# Northwest Biotherapeutics Inc: financial statements, quarterly

NWBO · OTC · CIK 1072379 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nwbo.md) · [Financials](/companies/nwbo/financials.md) · [Filings](/companies/nwbo/filings.md) · [Insiders](/companies/nwbo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nwbo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.4](/filings/0001410578-24-001879.md) | [0.4 d](/filings/0001410578-25-000598.md) | [0.3](/filings/0001410578-25-001333.md) | [0.5](/filings/0001410578-25-001825.md) | [0.4](/filings/0001104659-25-112676.md) | [0.2 d](/filings/0001104659-26-043806.md) | [0.4](/filings/0001104659-26-062661.md) | [0.1](/filings/0001104659-26-097188.md) | [0.2](/filings/0001104659-25-112676.md) | [0.7 d](/filings/0001104659-26-043806.md) | [0.5](/filings/0001104659-26-062661.md) | [0.8](/filings/0001104659-26-097188.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [7.2](/filings/0001410578-24-001879.md) | [7.5 d](/filings/0001410578-25-000598.md) | [7.9](/filings/0001410578-25-001333.md) | [8.3](/filings/0001410578-25-001825.md) | [8.1](/filings/0001104659-25-112676.md) | [10.5 d](/filings/0001104659-26-043806.md) | [8.4](/filings/0001104659-26-062661.md) | [7.4](/filings/0001104659-26-097188.md) | [7.5](/filings/0001104659-25-112676.md) | [5.6 d](/filings/0001104659-26-043806.md) | [4.9](/filings/0001104659-26-062661.md) | [5.7](/filings/0001104659-26-097188.md) |
| Operating income | $m | [(13.8)](/filings/0001410578-24-001879.md) | [(15.1) d](/filings/0001410578-25-000598.md) | [(15.7)](/filings/0001410578-25-001333.md) | [(17.5)](/filings/0001410578-25-001825.md) | [(14.8)](/filings/0001104659-25-112676.md) | [(18.5) d](/filings/0001104659-26-043806.md) | [(17.3)](/filings/0001104659-26-062661.md) | [(14.8)](/filings/0001104659-26-097188.md) | [(14.3)](/filings/0001104659-25-112676.md) | [(13.5) d](/filings/0001104659-26-043806.md) | [(10.9)](/filings/0001104659-26-062661.md) | [(11.6)](/filings/0001104659-26-097188.md) |
| Interest expense | $m | [1.7](/filings/0001410578-23-002304.md) | [1.2 d](/filings/0001410578-24-000133.md) | [1.5](/filings/0001410578-24-000741.md) | [1.7](/filings/0001410578-25-001825.md) | [2.1](/filings/0001104659-25-112676.md) | [2.5 d](/filings/0001104659-26-043806.md) | [1.6](/filings/0001104659-26-062661.md) | [1.8](/filings/0001104659-26-097188.md) | [2.6](/filings/0001104659-25-112676.md) | [2.6 d](/filings/0001104659-26-043806.md) | [2.3](/filings/0001104659-26-062661.md) | [1.8](/filings/0001104659-26-097188.md) |
| Net income | $m | [(23.5)](/filings/0001410578-24-001879.md) | [(14.0) d](/filings/0001410578-25-000598.md) | [(18.3)](/filings/0001410578-25-001333.md) | [(17.9)](/filings/0001410578-25-001825.md) | [(19.4)](/filings/0001104659-25-112676.md) | [(28.2) d](/filings/0001104659-26-043806.md) | [(19.3)](/filings/0001104659-26-062661.md) | [(15.4)](/filings/0001104659-26-097188.md) | [(26.8)](/filings/0001104659-25-112676.md) | [1.4 d](/filings/0001104659-26-043806.md) | [(3.1)](/filings/0001104659-26-062661.md) | [(9.2)](/filings/0001104659-26-097188.md) |
| Diluted EPS | $ per share | [(0.02)](/filings/0001410578-24-001879.md) | not reported | [(0.02)](/filings/0001410578-25-001333.md) | [(0.02)](/filings/0001410578-25-001825.md) | [(0.02)](/filings/0001104659-25-112676.md) | not reported | [(0.01)](/filings/0001104659-26-062661.md) | [(0.01)](/filings/0001104659-26-097188.md) | [(0.02)](/filings/0001104659-25-112676.md) | not reported | [0.00](/filings/0001104659-26-062661.md) | [(0.01)](/filings/0001104659-26-097188.md) |
| Basic EPS | $ per share | [(0.02)](/filings/0001410578-24-001879.md) | not reported | [(0.02)](/filings/0001410578-25-001333.md) | [(0.02)](/filings/0001410578-25-001825.md) | [(0.02)](/filings/0001104659-25-112676.md) | not reported | [(0.01)](/filings/0001104659-26-062661.md) | [(0.01)](/filings/0001104659-26-097188.md) | [(0.02)](/filings/0001104659-25-112676.md) | not reported | [0.00](/filings/0001104659-26-062661.md) | [(0.01)](/filings/0001104659-26-097188.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [6.1](/filings/0001410578-23-002304.md) | [2.1](/filings/0001410578-25-000598.md) | [2.5](/filings/0001410578-24-000741.md) | [2.9](/filings/0001410578-24-001278.md) | [2.9](/filings/0001410578-24-001879.md) | [2.2](/filings/0001104659-26-043806.md) | [2.8](/filings/0001410578-25-001333.md) | [4.3](/filings/0001410578-25-001825.md) | [4.6](/filings/0001104659-25-112676.md) | [3.0](/filings/0001104659-26-097188.md) | [1.8](/filings/0001104659-26-062661.md) | [0.6](/filings/0001104659-26-097188.md) |
| Current assets | $m | [8.5](/filings/0001410578-23-002304.md) | [4.1](/filings/0001410578-25-000598.md) | [4.9](/filings/0001410578-24-000741.md) | [5.0](/filings/0001410578-24-001278.md) | [5.2](/filings/0001410578-24-001879.md) | [4.1](/filings/0001104659-26-043806.md) | [4.7](/filings/0001410578-25-001333.md) | [6.2](/filings/0001410578-25-001825.md) | [7.2](/filings/0001104659-25-112676.md) | [5.5](/filings/0001104659-26-097188.md) | [6.2](/filings/0001104659-26-062661.md) | [2.6](/filings/0001104659-26-097188.md) |
| Total assets | $m | [31.5](/filings/0001410578-23-002304.md) | [27.9](/filings/0001410578-25-000598.md) | [28.6](/filings/0001410578-24-000741.md) | [28.2](/filings/0001410578-24-001278.md) | [29.3](/filings/0001410578-24-001879.md) | [26.7](/filings/0001104659-26-043806.md) | [27.5](/filings/0001410578-25-001333.md) | [29.5](/filings/0001410578-25-001825.md) | [30.6](/filings/0001104659-25-112676.md) | [81.3](/filings/0001104659-26-097188.md) | [80.1](/filings/0001104659-26-062661.md) | [75.9](/filings/0001104659-26-097188.md) |
| Current liabilities | $m | [49.2](/filings/0001410578-23-002304.md) | [45.2](/filings/0001410578-25-000598.md) | [62.4](/filings/0001410578-24-000741.md) | [56.2](/filings/0001410578-24-001278.md) | [59.6](/filings/0001410578-24-001879.md) | [68.3](/filings/0001104659-26-043806.md) | [83.1](/filings/0001410578-25-001333.md) | [83.9](/filings/0001410578-25-001825.md) | [87.9](/filings/0001104659-25-112676.md) | [91.7](/filings/0001104659-26-097188.md) | [83.0](/filings/0001104659-26-062661.md) | [73.4](/filings/0001104659-26-097188.md) |
| Total liabilities | $m | [68.9](/filings/0001410578-23-002304.md) | [74.9](/filings/0001410578-25-000598.md) | [82.0](/filings/0001410578-24-000741.md) | [86.0](/filings/0001410578-24-001278.md) | [93.6](/filings/0001410578-24-001879.md) | [106](/filings/0001104659-26-043806.md) | [112](/filings/0001410578-25-001333.md) | [116](/filings/0001410578-25-001825.md) | [126](/filings/0001104659-25-112676.md) | [129](/filings/0001104659-26-097188.md) | [118](/filings/0001104659-26-062661.md) | [111](/filings/0001104659-26-097188.md) |
| Long-term debt | $m | [32.9](/filings/0001410578-23-002304.md) | [40.8](/filings/0001410578-25-000598.md) | [44.4](/filings/0001410578-24-000741.md) | [51.0](/filings/0001410578-24-001278.md) | [53.3](/filings/0001410578-24-001879.md) | [62.7](/filings/0001104659-26-043806.md) | [64.1](/filings/0001410578-25-001333.md) | [64.7](/filings/0001410578-25-001825.md) | [72.2](/filings/0001104659-25-112676.md) | [60.0](/filings/0001104659-26-097188.md) | [59.4](/filings/0001104659-26-062661.md) | [52.0](/filings/0001104659-26-097188.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(70.1)](/filings/0001410578-24-001879.md) | [(65.8)](/filings/0001104659-26-043806.md) | [(73.3)](/filings/0001410578-25-001825.md) | [(76.5)](/filings/0001104659-25-112676.md) | [(80.1)](/filings/0001104659-25-112676.md) | [(94.5)](/filings/0001104659-26-097188.md) | [(99.5)](/filings/0001104659-26-097188.md) | [(100)](/filings/0001104659-26-097188.md) | [(109)](/filings/0001104659-25-112676.md) | [(60.3)](/filings/0001104659-26-097188.md) | [(50.5)](/filings/0001104659-26-097188.md) | [(45.2)](/filings/0001104659-26-097188.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.9) d](/filings/0001410578-24-001879.md) | [(17.0) d](/filings/0001410578-25-000598.md) | [(12.4)](/filings/0001410578-25-001333.md) | [(16.2) d](/filings/0001410578-25-001825.md) | [(8.2) d](/filings/0001104659-25-112676.md) | [(20.2) d](/filings/0001104659-26-043806.md) | [(9.4)](/filings/0001104659-26-062661.md) | [(6.7) d](/filings/0001104659-26-097188.md) | [(13.9) d](/filings/0001104659-25-112676.md) | [(14.8) d](/filings/0001104659-26-043806.md) | [(12.5)](/filings/0001104659-26-062661.md) | [(7.2) d](/filings/0001104659-26-097188.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001410578-24-001879.md) | not reported | [0.2](/filings/0001410578-25-001333.md) | [0.5 d](/filings/0001410578-25-001825.md) | [0.2 d](/filings/0001104659-25-112676.md) | [0.1 d](/filings/0001104659-26-043806.md) | [0.1](/filings/0001104659-26-062661.md) | [0.3 d](/filings/0001104659-26-097188.md) | [0.2 d](/filings/0001104659-25-112676.md) | [0.9 d](/filings/0001104659-26-043806.md) | [0.1](/filings/0001104659-26-062661.md) | [0.2 d](/filings/0001104659-26-097188.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.0](/filings/0001410578-23-002304.md) | [1.1](/filings/0001410578-24-000741.md) | [1.1](/filings/0001410578-24-001278.md) | [1.1](/filings/0001410578-24-001879.md) | [1.2](/filings/0001410578-25-001333.md) | [1.2](/filings/0001410578-25-001825.md) | [1.3](/filings/0001104659-25-112676.md) | [1,359](/filings/0001104659-26-062661.md) | [1,438](/filings/0001104659-26-097188.md) | [1.5](/filings/0001104659-25-112676.md) | [1,585](/filings/0001104659-26-062661.md) | [1,642](/filings/0001104659-26-097188.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,705,637,993 at 2026-08-13, from the cover of the [10-Q filed 2026-08-14](/filings/0001104659-26-097188.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.